Overview

Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma

Status:
RECRUITING
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
Radiopharmaceutical in Relapsed/Refractory Neuroblastoma
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Sichuan University